- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Lomilan is a histamine H1 receptor blocker for systemic use. It has antiallergic, antipruritic and antiexudative action.
Reduces capillary permeability, prevents the development of tissue edema, relieves spasms of smooth muscles.
Does not affect the central nervous system and is not addictive. The effect of the drug begins 30 minutes after administration, reaches a maximum after 8-12 hours and lasts for 24 hours.
Prevention and treatment of the following diseases and conditions:
- seasonal and perennial allergic rhinitis;
- allergic conjunctivitis;
- treatment of skin diseases of allergic genesis (including chronic idiopathic urticaria);
- pseudo-allergic reactions;
- allergic reactions to insect bites.
1 tablet contains Loratadine - 10 mg;
Excipients: lactose, corn starch, gelatinized starch, magnesium stearate.
Loratadine is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Claritin||Bayer Pharma AG||Germany||pills|
|Claritin||Bayer Pharma AG||Germany||syrup|
No customer reviews for the moment.
Dosage and Administration
Adults and children over 12 years old, as well as younger children weighing more than 30 kg, are prescribed 1 tablet 1 time per day.
For patients with impaired liver function or renal failure, the initial dose of the drug is 10 mg every other day.
pills are taken orally (possibly simultaneously with a meal), drinking water or milk. If necessary, the tablet can be chewed.
Children under 12 years old are recommended to use the suspension.
In adults: dry mouth, nausea, gastritis, headache, fatigue, drowsiness; rarely, liver dysfunction, allergic reactions (rash), anaphylactic reactions, alopecia.
In children: rarely - headache, nervousness, sedation.
The frequency of these side effects with Lomilan was at the same level as with placebo.
Hypersensitivity to all components of the drug (pills or suspensions).
WITH caution prescribe the drug for liver failure. There is no data on the safety and efficacy of Lomilan in children under 2 years of age.
With simultaneous use with ketoconazole and cimetidine concentration of loratadine in the blood increases.
The simultaneous intake of microsomal oxidation inducers (phenytoin, ethanol, barbiturates, rifampicin, tricyclic antidepressants) reduces the effectiveness of loratadine.
Pregnancy and Lactation
Use of Lomilan during pregnancy is possible only when the intended benefit to the mother outweighs the potential risk to the fetus.
Loratadine is excreted in breast milk, so if necessary, the appointment of the drug during lactation should decide on the termination of breastfeeding.
The drug should be discontinued at least 2 days before skin allergy tests, because Lomilan can influence their results.
Influence on ability to drive motor transport and control mechanisms
There are no data on the negative effect of Lomilan in recommended doses on the ability to drive a car or work with mechanisms. However, when using Lomilan in doses higher than recommended, or when nonstandard effects appear after taking the drug, care should be taken when practicing potentially hazardous activities that require high concentration of attention and speed of psychomotor reactions.
Symptoms: headache, drowsiness, palpitations that can last a long time.
Treatment: when taking an excessive amount of Lomilan, remove the drug from the gastrointestinal tract as soon as possible and, if possible, reduce its absorption (gastric lavage, taking activated charcoal). There is no specific antidote.
- Brand name: Lomilan
- Active ingredient: Loratadine
- Dosage form: Pills.
- Manufacturer: Sandoz
- Country of Origin: Switzerland
Studies and clinical trials of Loratadine (Click to expand)
- Stability-indicating micelle-enhanced spectrofluorimetric method for determination of loratadine and desloratadine in dosage forms
- Enhanced bioavailability and antihistamine effects by transdermal administration of loratadine gels containing an enhancer in rats
- Comparatice effects of loratadine and selected antihistamines on sleep-waking patterns in the cat
- Pharmacologic modulation by cetirizine 2 HCl and loratadine of the histamine-induced skin reaction in mice and in humans
- Brain histamine H1 receptor occupancy of loratadine measured by positron emission topography: comparison of H1 receptor occupancy and proportional impairment ratio
- General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism
- Checkpoint kinase 1-mediated phosphorylation of Cdc25C and bad proteins are involved in antitumor effects of loratadine-induced G2/M phase cell-cycle arrest and apoptosis
- Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations*
- Sensitive gas—liquid chromatographic method for the determination of loratadine and its major active metabolite, descarboethoxyloratadine, in human plasma using a nitrogen—phosphorus detector
- Determination of loratadine and pheniramine from human serum by gas chromatography-mass spectrometry
- Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity
- Synthesis and antihistamine evaluations of novel loratadine analogues
- Determination of loratadine in human plasma by liquid chromatography electrospray ionization ion-trap tandem mass spectrometry
- Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma
- Rapid determination of loratadine in small volume plasma samples by high-performance liquid chromatography with fluorescence detection
- Preparation and coating of finely dispersed drugs: 4. Loratadine and danazol
- Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography–electrospray mass spectrometry for pharmacokinetic studies
- Determination of loratadine and its active metabolite in human plasma by high-performance liquid chromatography with mass spectrometry detection
- Simultaneous determination of loratadine and desloratadine in pharmaceutical preparations using liquid chromatography with a microemulsion as eluent
- Degradation product of loratadine
- Water-soluble loratadine inclusion complex: Analytical control of the preparation by microwave irradiation
- Curve-fitting FTIR studies of loratadine/hydroxypropyl-β-cyclodextrin inclusion complex induced by co-grinding process
- Physico-chemical characterization and in vitro/in vivo evaluation of loratadine:dimethyl-β-cyclodextrin inclusion complexes
- Sensitive liquid chromatography–tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma